Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
| Status: | Archived |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | July 2009 |
| End Date: | July 2011 |
This is a single arm study of 20 men with treatment refractory metastatic CRPC who will
receive temsirolimus IV at a dose of 25 mg weekly until progression. Progression will not
include PSA progression; however, upon PSA progression, the addition of an anti-androgen
will be permitted. The primary objective of the study is to evaluate change in circulating
tumor cell (CTC) counts over time in men with metastatic treatment-refractory CRPC in
response to temsirolimus therapy.
We found this trial at
2
sites
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
Click here to add this to my saved trials